South Florida Hospital News
Tuesday November 24, 2020

test 2

November 2020 - Volume 17 - Issue 5


Novel Radiation Technology at Miami Cancer Institute Improves Quality of Life

An advanced form of radiation therapy available at Miami Cancer Institute may extend overall survival and improve quality of life for patients with inoperable pancreas cancer. The ViewRayTM MRIdian MR-Linac technology safely delivers an unprecedented high dose of radiation over just five consecutive days directly to the tumor using continuous real-time MRI scans. The images ensure millimeter accuracy and also allow for treatment to be adapted daily to account for changes in the patient’s internal anatomy. Known as MR-guided stereotactic ablative radiation therapy (SABR), this state-of-the-art treatment is painless, completely non-invasive and requires no anesthesia or needles. Miami Cancer Institute was the second cancer center in the U.S. to begin treating patients with this technology in April 2018.

Investigators from Miami Cancer Institute recently published the first clinical outcomes of chemotherapy followed by MR-guided SABR on an MR-Linac for inoperable pancreas cancer in Practical Radiation Oncology using nearly twice the radiation dose that is safely deliverable on a standard radiation delivery machine. The study included 35 patients ranging in age from 34 to 89 years and reported that one year after SABR nearly 90% of patients had their cancer controlled locally and almost 60% of patients were alive, both of which are favorable compared to historical outcomes with lower radiation dose. Some patients who initially had inoperable pancreas cancer ultimately were able to undergo successful surgery because of excellent response after SABR.
“A significant number of our patients have surpassed the expected survival for this deadly disease, with many alive several years after their initial diagnosis,” said Michael Chuong, M.D., director of MRI-Guided Radiation Therapy at Miami Cancer Institute and a radiation oncologist specializing in gastrointestinal cancers. In fact, Dr. Chuong is encouraged that patient survival beyond two years after initial diagnosis may be more than doubled through the use of ablative radiation dose versus lower radiation dose. He anticipates publishing long-term survival outcomes in the near future.
Dr. Chuong notes that not only has the efficacy of MR-guided SABR been excellent for pancreas cancer, but it also has been very well tolerated, with only about 3% of patients experiencing serious side effects and the majority experiencing little to no side effects. “It is remarkable that we have seen such little treatment toxicity given the incredibly high radiation dose that is delivered to tumors in the pancreas that are surrounded by ― and sometimes literally touching ― the stomach and intestines,” he said. “Patients are in and out within about an hour. They go back to work or play golf, and do their normal activities.”
Share |